Older melanoma patients have better response to immune checkpoint blockade therapy – Patient age correlates…

Older melanoma patients have better response to immune checkpoint blockade therapy – Patient age correlates with response to immunotherapy in melanoma and depleting regulatory T cells in young patients may have a therapeutic potential to enhance response in younger patients, according to research from The Wistar Institute. Study results were published online in Clinical Cancer Research.

Older melanoma patients have better response to immune checkpoint blockade therapy

Source: +Medicalxpress
Older melanoma patients have better response to immune checkpoint blockade therapy – Patient age correlates…